Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 772 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Biosimilars for Cancer Emerge as Patents on Widely Used Biological Drugs... June 18, 2018 Antitumour Activity of Combination of Lenvatinib and Pembrolizumab in Patients with... August 2, 2022 EMA Recommends Granting a Marketing Authorisation for Generic Enzalutamide August 9, 2024 Helping Cancer Survivors Cope with Cancer-Related Anxiety and Distress April 30, 2020 Load more HOT NEWS 4 Ways to Manage Setbacks in Your Cancer Recovery: A Young... ESMO Breast Cancer Congress 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Repotrectinib A Robust, Durable Activity of Atezolizumab Observed in a Diverse Cohort...
